<?xml version='1.0' encoding='utf-8'?>
<document id="31353479"><sentence text="Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease."><entity charOffset="10-23" id="DDI-PubMed.31353479.s1.e0" text="Lercanidipine" /><entity charOffset="68-78" id="DDI-PubMed.31353479.s1.e1" text="Carvedilol" /><pair ddi="false" e1="DDI-PubMed.31353479.s1.e0" e2="DDI-PubMed.31353479.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31353479.s1.e0" e2="DDI-PubMed.31353479.s1.e1" /></sentence><sentence text="This study evaluates the carvedilol-lercanidipine drug interaction, and the influence of chronic kidney disease (CKD) on both drugs" /><sentence text=" Patients with high blood pressure (8 with normal renal function [control] and 8 with CKD with estimated glomerular filtration rate categories of G3b to G5 [12-38 mL/min/1" /><sentence text="73 m2 ]) were included and prescribed 3 different treatment regimens, a single oral dose of racemic carvedilol 25 mg (CAR), a single oral dose of racemic lercanidipine 20 mg (LER), and single oral doses of CAR plus LER"><entity charOffset="146-167" id="DDI-PubMed.31353479.s4.e0" text="racemic lercanidipine" /></sentence><sentence text=" Blood samples were collected and variations in heart rate were assessed (using isometric exercise with handgrip) for up to 32 hours" /><sentence text=" Lercanidipine pharmacokinetics were not enantioselective, and were not affected by carvedilol and CKD"><entity charOffset="1-14" id="DDI-PubMed.31353479.s6.e0" text="Lercanidipine" /><entity charOffset="84-94" id="DDI-PubMed.31353479.s6.e1" text="carvedilol" /><pair ddi="false" e1="DDI-PubMed.31353479.s6.e0" e2="DDI-PubMed.31353479.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31353479.s6.e0" e2="DDI-PubMed.31353479.s6.e1" /></sentence><sentence text=" Carvedilol pharmacokinetics (data presented as median) were enantioselective with higher plasma exposure of (R)-(+)-carvedilol in both control (103"><entity charOffset="1-11" id="DDI-PubMed.31353479.s7.e0" text="Carvedilol" /><entity charOffset="109-127" id="DDI-PubMed.31353479.s7.e1" text="(R)-(+)-carvedilol" /><pair ddi="false" e1="DDI-PubMed.31353479.s7.e0" e2="DDI-PubMed.31353479.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31353479.s7.e0" e2="DDI-PubMed.31353479.s7.e1" /></sentence><sentence text="5 vs 46" /><sentence text="0 ng ∙ h/mL) and CKD (190" /><sentence text="6 vs 98" /><sentence text="9 ng ∙ h/mL) groups" /><sentence text=" Lercanidipine increased the area under the plasma concentration-time curve of only (R)-(+)-carvedilol in the CKD group (190"><entity charOffset="1-14" id="DDI-PubMed.31353479.s12.e0" text="Lercanidipine" /><entity charOffset="84-102" id="DDI-PubMed.31353479.s12.e1" text="(R)-(+)-carvedilol" /><pair ddi="false" e1="DDI-PubMed.31353479.s12.e0" e2="DDI-PubMed.31353479.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31353479.s12.e0" e2="DDI-PubMed.31353479.s12.e1" /></sentence><sentence text="6 vs 242" /><sentence text="2 ng ∙ h/mL) but not in the control group (103" /><sentence text="5 vs 98" /><sentence text="7 ng ∙ h/mL)" /><sentence text=" CKD increased plasma exposure (46" /><sentence text="0 vs 98" /><sentence text="9 ng ∙ h/mL) and effect-compartment exposure (5" /><sentence text="5 vs 20" /><sentence text="9 ng ∙ h/mL) to (S)-(-)-carvedilol, resulting in higher β-adrenergic inhibition (10"><entity charOffset="16-34" id="DDI-PubMed.31353479.s21.e0" text="(S)-(-)-carvedilol" /></sentence><sentence text="0 vs 6" /><sentence text="1 bpm)" /><sentence text=" Therefore, carvedilol dose titration in CKD patients with estimated glomerular filtration rate categories of G3b to G5 should be initiated, with no more than half the dose used for patients with normal renal function"><entity charOffset="12-22" id="DDI-PubMed.31353479.s24.e0" text="carvedilol" /></sentence><sentence text="" /></document>